Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Vincristine 7Cyclophosphamide 710-propargyl-10-deazaaminopterin 7Prednisone 6Doxorubicin 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5romidepsin 3belinostat 3Gemcitabine 3liposomal doxorubicin 2duvelisib 1Vitamin B 12 1MLN 8237 1Folic Acid 1Etoposide 1E7777 fusion protein 1Decitabine 1CHOP protocol 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1BAEC protocol 1Alemtuzumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell, Peripheral × E7777 fusion protein × Clear all
NCT01355783 2013-11-18

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

Eisai Inc.

Phase 3 Withdrawn
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡